3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
4
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
5
Specimen Handling
3
Cyclophosphamide
3
Biopsy
3
ibrutinib
2
fludarabine
2
binimetinib
2
Vemurafenib
2
Cladribine
2
venetoclax
1
tovorafenib
1
polatuzumab vedotin
1
pembrolizumab
1
obinutuzumab
1
immunotoxin HA22
1
fludarabine phosphate
1
encorafenib
1
brexucabtagene autoleucel
1
acalabrutinib
1
Whole-Body Irradiation
1
Transplantation
1
Tacrolimus
1
Spinal Puncture
1
Radiotherapy
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
High-Energy Shock Waves
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
90 days
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts